The Latest Analyst Ratings for Pacific Biosciences
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received mixed analyst ratings in the last quarter, with 2 bullish and 2 indifferent ratings. The average 12-month price target for the company has increased by 17.31% from the previous average of $13.00 to $15.25.
August 04, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and an increased price target could lead to volatility in Pacific Biosciences' stock price.
The mixed analyst ratings indicate uncertainty about the company's future performance. The increased price target suggests that analysts see potential for growth, but the presence of indifferent ratings means that not all analysts are convinced. This could lead to volatility in the stock price as investors react to these differing opinions.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100